Accurate Education - Nutraceutical Protocols: Migraine Headaches

Nutraceutical Protocols:

Migraine Headaches

Nutraceuticals are commonly recommended for migraine headaches. They offer the potential to reduce attack frequency, duration, and intensity, and are generally considered safe, though they may have only modest effectiveness compared to prescription drugs.

See:

Nutraceutical Protocols:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Nutraceutical Protocols:

Migraine Headaches

Migraine is a complex neurovascular disorder affecting approximately 12% of the population (6% of men, 18% of women).[1][2] The pathophysiology involves multiple mechanisms in which intervention with nutraceuticals may have favorable impact on severity and frequency of migraine headaches. [3][4][1] Nutraceuticals targeting these mechanisms have demonstrated effectiveness in migraine prevention, with several receiving conventional migraine management guideline-level recommendations.

Pathophysiology Targeted:

Trigeminovascular system activation,
Release of CGRP and other neuropeptides
Neuroinflammation,
Oxidative stress,
Mitochondrial Dysfunction
Cortical hyperexcitability
Central Sensitization,
NMDA receptor dysregulation
Meningeal neurogenic inflammation

The following figure illustrates the anatomy and pathogenesis of migraine, showing the trigeminovascular system and molecular pathways involved:

Figure 1 Anatomy and Pathogenesis of Migraine—

EVIDENCE SUMMARY FOR NUTRACEUTICALS IN MIGRAINE

A 2025 dose-response meta-analysis of 22 studies provides the most comprehensive evidence for nutraceutical efficacy in migraine prophylaxis:[6]

Nutraceutical	Migraine Attacks (MD)	Severity (MD)	Duration (MD)	Monthly Migraine Days (MD)	References
Magnesium	-2.51	-0.88	NS	-1.66	[1]
CoQ10	-1.73	-1.35	-1.72	NS	[1]
Riboflavin	-1.34	NS	NS	NS	[1]
Alpha-Lipoic Acid	-1.24	-0.38	NS	NS	[1]
Probiotics	-1.16	-1.07	NS	-3.02	[1]
Vitamin D	-1.69	NS	NS	-2.41	[1]

[6]

—

NUTRACEUTICAL PROTOCOL FOR MIGRAINE

Tier 1: Core Agents (Strongest Evidence)

Agent	Dosing Protocol	Evidence Level	Mechanism/Rationale	References
Magnesium	400–600 mg daily (citrate or glycinate); IV 1–2 g for acute attacks	Level B (AAN/AHS); GRADE: Strong evidence	NMDA receptor antagonism; reduces cortical spreading depression; reduces CGRP release; mean reduction 2.51 attacks/month	[1], [2], [3], [4], [5], [6]
Riboflavin (Vitamin B2)	400 mg daily	Level B (AAN/AHS)	Enhances mitochondrial energy metabolism; addresses mitochondrial dysfunction in migraine; >50% reduction in attacks in >50% of patients	[7], [8], [9]
CoQ10	100–400 mg daily (typically 300 mg)	Level C (AAN/AHS)	Mitochondrial cofactor; reduces oxidative stress; 50% responder rate 47.6% vs 14.4% placebo (NNT=3)	[10], [11], [12]
Melatonin	3 mg immediate-release QHS	Moderate evidence; non-inferior to amitriptyline	NLRP3 inflammasome inhibition; circadian regulation; reduces headache days, severity, analgesic use; better tolerated than amitriptyline	[13], [14], [15], [16], [17]

[24][6][25][26][27][28][29][30][31][32][33][34][35][36][37][38]

Magnesium Evidence: An umbrella review found strong GRADE evidence for magnesium reducing migraine frequency and intensity.[30] A meta-analysis of 21 RCTs (1,737 participants) showed IV magnesium significantly relieved acute migraine within 15–45 minutes (OR 0.23), and oral magnesium significantly reduced frequency (OR 0.20) and intensity (OR 0.27).[29] The VA/DoD Headache Guidelines recommend magnesium 400–600 mg daily for migraine prophylaxis.[27]
Riboflavin Evidence: The 2012 AAN/AHS guideline rated riboflavin as Level B (probably effective) for migraine prevention.[25] Daily intake of 400 mg riboflavin for 3 months resulted in >50% reduction in migraine attacks in more than half of consumers.[31]
CoQ10 Evidence: A landmark RCT showed CoQ10 (3 × 100 mg/day) achieved a 50% responder rate of 47.6% vs 14.4% for placebo (NNT=3).[33] The 2012 AAN/AHS guideline rated CoQ10 as Level C (possibly effective).[25]
Melatonin Evidence: A 2026 meta-analysis of 9 RCTs (n=788) found melatonin significantly reduced attack duration (-4.98 hours), headache days (-1.54 days), severity (-2.08), and analgesic use (-1.38) compared to placebo, with a 38% higher response rate (RR 1.38).[35] Melatonin 3 mg was non-inferior to amitriptyline 25 mg with better tolerability.[37]

—

Tier 2: Emerging Evidence Agents

Agent	Dosing Protocol	Evidence Level	Mechanism/Rationale	References
PEA (Palmitoylethanolamide)	600 mg 2x/day (acute); 600 mg 2x/day prophylaxis	Emerging clinical evidence	Reduces neurogenic inflammation; modulates endocannabinoid system; plasma PEA increases during migraine attacks; Reduces pain, duration, medication use	[1], [2], [3], [4], [5]
Curcumin	80 mg nano-curcumin daily; or 500 mg high-bioavailability TID	Preliminary positive evidence	Anti-inflammatory; reduces TNF-α, oxidative stress; synergistic with CoQ10 and omega-3	[6], [7], [8], [9], [10]
Omega-3 (EPA/DHA)	1.5–2 g EPA+DHA daily	Mixed evidence; positive for dietary intervention	Reduces neuroinflammation; increases anti-nociceptive mediators (17-HDHA); dietary intervention reduced headache days by 4/month	[11], [12], [13], [14]
Alpha-Lipoic Acid (ALA)	600 mg daily	Meta-analysis positive	Antioxidant; mitochondrial support; reduced attack frequency (MD -1.24) and severity (MD -0.38)	[15]

[6][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54]

PEA Evidence: A 2024 double-blind RCT found PEA (600 mg) resolved more headaches at 2 and 8 hours, had lower pain scores at 1.5 and 4 hours, and reduced rescue medication use compared to placebo for acute migraine treatment.[39] A pilot study of PEA-based nutraceutical for migraine prophylaxis showed headache days decreased from 10 to 6.6 days/month (p<0.00001) and analgesic use decreased from 9.2 to 4.1 days (p<0.0001).[40]
Curcumin + CoQ10 Synergy: An RCT of nano-curcumin (80 mg) + CoQ10 (300 mg) showed synergistic effects on migraine frequency, severity, duration, and disability compared to either agent alone or placebo (all p<0.001).[48]
Omega-3 Evidence: The landmark 2021 BMJ trial (n=182) found that increasing dietary EPA+DHA to 1.5 g/day reduced headache days by 4 days/month compared to control, with additional benefit from lowering linoleic acid.[51] A 2024 RCT of high-dose EPA (1.8 g/day) reduced monthly migraine days by 4.4 days vs 0.6 days for placebo (p=0.001).[52]

—

Tier 3: Supporting Agents

Agent	Dosing Protocol	Evidence Level	Mechanism/Rationale	References
Vitamin D3	Optimize to 25(OH)D level ≥40 ng/mL	Meta-analysis positive	Reduces migraine frequency, monthly days deficiency common in migraineurs	[1], [2]
Feverfew	50–75 mg 2x/day	Level B (AAN/AHS 2012)	Inhibits prostaglandin synthesis; anti-inflammatory; avoid in pregnancy	[3], [4]
Probiotics	Multi-strain formulation	Meta-analysis positive	Gut-brain axis modulation; reduces frequency, severity, monthly days	[5]

[24][6][25][31]

—

COMPREHENSIVE MIGRAINE PROTOCOL

Phase 1: Foundation (Weeks 1–4)

Goal: Establish core nutraceutical support

Magnesium (citrate or glycinate): 400–600 mg daily (start 200 mg, titrate up to minimize GI effects)
Riboflavin (B2): 400 mg daily
CoQ10: 100–300 mg daily
Melatonin: 3 mg immediate-release QHS (if sleep issues or as alternative to other prophylactics)

Phase 2: Intensification (Weeks 4–12)

Goal: Add agents based on response and migraine characteristics

Continue Phase 1 agents
Add PEA: 600 mg BID (especially if neuroinflammatory component suspected)
Add Omega-3: 1.5–2 g EPA+DHA daily
Consider Curcumin: 80 mg nano-curcumin or 500 mg high-bioavailability TID

Phase 3: Optimization (Weeks 12+)

Goal: Personalize based on response

Continue effective agents
Add Alpha-Lipoic Acid: 600 mg daily if mitochondrial dysfunction suspected
Optimize Vitamin D3 to 40–60 ng/mL
Consider Feverfew: 50–75 mg BID (avoid in pregnancy)

—

MIGRAINE SUBTYPE-SPECIFIC CONSIDERATIONS

Migraine Subtype	Priority Nutraceuticals	Rationale	References
Migraine with Aura	Magnesium (high priority), Riboflavin, CoQ10	Magnesium reduces cortical spreading depression; mitochondrial support	[1], [2]
Chronic Migraine	Full protocol; emphasize PEA, Melatonin	Central sensitization; neuroinflammation; sleep disruption	[3], [4]
Menstrual Migraine	Magnesium (perimenstrual loading), Vitamin D, Omega-3	Magnesium safe in pregnancy; hormonal modulation	[5]
Vestibular Migraine (Vertigo)	Magnesium, Riboflavin, CoQ10	Standard migraine prophylaxis applies	[6]
Medication Overuse Headache	PEA, Melatonin, Magnesium	Reduce analgesic dependence; Addresses central sensitization	[7]

[24][6][39][40][35]

—

ACUTE MIGRAINE TREATMENT

Agent	Dosing	Evidence	Mechanism	References
IV Magnesium	1–2 g IV over 15–30 minutes	Meta-analysis: OR 0.23 for relief at 15–45 min	NMDA antagonism; vasodilation	[1], [2]
PEA	600 mg at onset; repeat at 2 hours if needed	Resolved more headaches at 2h and 8h vs placebo	Reduces neurogenic inflammation	[3]
Ginger	250 mg powder	Non-inferior to sumatriptan 50 mg in one RCT	Anti-inflammatory; 5-HT modulation	[4]

[26][29][39][46]

—

INTEGRATION WITH PHARMACOTHERAPY

Nutraceuticals should complement, not replace, standard migraine prophylaxis when indicated. They may allow dose reduction of medications or serve as first-line therapy in patients preferring non-pharmacological approaches.

Pharmacotherapy	Nutraceutical Synergy	Considerations	References
Beta-blockers	Magnesium, CoQ10	CoQ10 may offset beta-blocker-induced CoQ10 depletion	[1]
Topiramate	Magnesium, Riboflavin	Both target similar pathways; may allow lower topiramate doses	[2]
Amitriptyline	Melatonin	Melatonin non-inferior with better tolerability; may allow lower TCA doses	[3]
CGRP (Nurtec, Ubelvy, Qulipta	Full protocol	Nutraceuticals target complementary pathways (oxidative stress, mitochondria)	[4]
Valproate	Magnesium, CoQ10	Magnesium comparable efficacy to valproate in one RCT	[5]

[24][27][32][37][55]

—

MONITORING AND ASSESSMENT

Baseline Assessment:

Headache diary: frequency, duration, severity, medication use
Laboratory: 25(OH)D, magnesium (RBC magnesium preferred), consider CoQ10 levels
Sleep quality assessment (PSQI)

Expected Timeline:

Weeks 1–4: Minimal effect expected; nutraceuticals require time to reach steady state
Weeks 4–8: Initial response may be observed
Weeks 8–12: Full assessment of efficacy; riboflavin and CoQ10 typically require 3 months
Beyond 12 weeks: Sustained benefit; consider dose optimization

—

SPECIAL POPULATIONS

Pregnancy:

Magnesium: Safe; first-line nutraceutical for pregnant migraineurs[24]
Riboflavin: Generally considered safe
CoQ10: Limited data; likely safe
Feverfew: Contraindicated (uterine contractions)[24]
Melatonin: Limited data; use with caution

Pediatric:

Riboflavin: Pediatric use not proven[26]
CoQ10: Some positive pediatric data
Magnesium: Generally safe
PEA: Pilot study showed efficacy in pediatric migraine (600 mg/day)[43]

Elderly:

Standard protocol with attention to renal function (magnesium)
Consider drug interactions with polypharmacy

—

PATIENT EDUCATION HANDOUT

Preventing Migraines with Natural Supplements: Your Guide

Understanding Migraine Prevention

Migraines are more than just headaches—they are a complex brain condition that can significantly impact your quality of life. While medications are often helpful, many people prefer to start with or add natural supplements that have been shown to help prevent migraines.

Research has identified several supplements that can reduce how often you get migraines, how severe they are, and how long they last. These supplements work by supporting your brain’s energy production, reducing inflammation, and calming overactive nerve signals.

—

Your Core Supplements

Magnesium – 400–600 mg daily

– One of the most well-studied supplements for migraine prevention

– Works by calming nerve signals and reducing the brain activity that triggers migraines

– Studies show it can reduce migraine attacks by about 2.5 per month

– Best forms: magnesium citrate or magnesium glycinate (better absorbed than oxide)

– Start with 200 mg and increase gradually to minimize stomach upset

– Can also be given by IV during a severe migraine attack

Riboflavin (Vitamin B2) – 400 mg daily

– Helps your brain cells produce energy more efficiently

– Studies show more than half of people taking riboflavin have at least 50% fewer migraines

– Very safe with minimal side effects

– May turn your urine bright yellow—this is normal and harmless

– Takes about 3 months to see full benefit

Coenzyme Q10 (CoQ10) – 100–300 mg daily

– Another supplement that supports brain energy production

– Studies show nearly half of people respond well (compared to only 14% on placebo)

– Very well tolerated with few side effects

– Works well in combination with other supplements

Melatonin – 3 mg at bedtime

– Best known for sleep, but also helps prevent migraines

– Studies show it reduces headache days, severity, and pain medication use

– Works as well as some prescription medications with fewer side effects

– Especially helpful if you have sleep problems along with migraines

—

Additional Helpful Supplements

PEA (Palmitoylethanolamide) – 600 mg twice daily

– A natural substance that reduces inflammation in your nervous system

– Can help both prevent migraines and treat them when they occur

– Studies show it reduces pain, duration, and need for other medications

Omega-3 Fish Oil – 1.5–2 grams of EPA+DHA daily

– Reduces inflammation that contributes to migraines

– A major study showed it reduced headache days by 4 per month

– Also good for heart and brain health

Alpha-Lipoic Acid – 600 mg daily

– A powerful antioxidant that supports brain energy

– Studies show it reduces migraine frequency and severity

—

What to Expect

Supplements work differently than medications—they support your body’s natural processes rather than blocking symptoms. This means:

– Be patient: Most supplements take 2–3 months to show full benefit

– Be consistent: Take supplements every day, even when you feel well

– Track your progress: Keep a headache diary to see if supplements are helping

Realistic expectations:

– A 50% reduction in migraine frequency is considered a good response

– Some people respond better than others

– Combining supplements often works better than single supplements

—

Tips for Success

1. Start one supplement at a time: This helps you identify what works and what causes any side effects

2. Take with food: Most supplements absorb better and cause less stomach upset when taken with meals

3. Be consistent: Take supplements at the same time each day

4. Give it time: Allow at least 3 months before deciding if a supplement is working

5. Keep a headache diary: Track your migraines, sleep, stress, and supplement use

6. Stay hydrated: Dehydration can trigger migraines

7. Maintain regular sleep: Irregular sleep is a common migraine trigger

—

Safety Information

These supplements are generally very safe, but keep these points in mind:

– Magnesium: May cause loose stools; start with a low dose and increase gradually

– Riboflavin: May turn urine bright yellow (harmless)

– CoQ10: Very well tolerated; rare mild stomach upset

– Melatonin: May cause drowsiness; take at bedtime only

– Feverfew: Do NOT take if pregnant or trying to become pregnant

When to Contact Your Healthcare Provider:

– If your migraines are getting worse

– If you develop new or different headache symptoms

– If you experience any concerning side effects

– If you’re not seeing improvement after 3 months

—

Working With Your Healthcare Team

These supplements can be used alone or alongside prescription migraine medications. Always tell your healthcare provider about all supplements you take. Together, you can find the best combination to reduce your migraines and improve your quality of life.

—

Clinical Implementation Notes

The evidence for nutraceuticals in migraine prophylaxis is substantial, with several agents receiving guideline-level recommendations. Magnesium has the strongest evidence, with an umbrella review finding strong GRADE evidence for reducing migraine frequency and intensity.[30] The 2012 AAN/AHS guideline rated magnesium, riboflavin, and feverfew as Level B (probably effective) and CoQ10 as Level C (possibly effective).[25]

Combination therapy appears more effective than single agents. The synergistic effects of nano-curcumin + CoQ10 and omega-3 + curcumin on TNF-α and clinical outcomes suggest multimodal approaches may be optimal.[48][50]

PEA represents an emerging option with both acute and prophylactic evidence. Its mechanism of modulating the endocannabinoid system and reducing neurogenic inflammation aligns with migraine pathophysiology.[42] Plasma PEA levels increase during migraine attacks, suggesting a compensatory anti-inflammatory response.[44]

Melatonin has gained substantial evidence, with a 2026 meta-analysis confirming efficacy across multiple outcomes.[35] Its favorable tolerability profile compared to amitriptyline makes it an attractive option, particularly for patients with comorbid sleep disturbance.

Important caveats: While nutraceuticals have demonstrated efficacy, effect sizes are generally modest (similar to many pharmacological prophylactics). The 2025 AAFP review notes that “studies on supplements continue to have small sample sizes and short durations” and that supplements “are not regulated in the United States.” Butterbur, despite Level A evidence for efficacy, is no longer recommended due to hepatotoxicity concerns from pyrrolizidine alkaloids.[24][26]

Would you like me to create a comprehensive summary document combining all eight condition-specific protocols, or develop monitoring flowsheets and drug-nutraceutical interaction tables for clinical implementation?

References

Migraine. Dodick DW. Lancet (London, England). 2018;391(10127):1315-1330. doi:10.1016/S0140-6736(18)30478-1.
Glia Signaling and Brain Microenvironment in Migraine. Amani H, Soltani Khaboushan A, Terwindt GM, Tafakhori A. Molecular Neurobiology. 2023;60(7):3911-3934. doi:10.1007/s12035-023-03300-3.
Exploring the Epigenetic Modifications of the RONS-TRPA1-CGRP Axis in Migraine Pathophysiology. Fila M, Pawlowska E, Krekora J, Mitus-Kenig M, Blasiak J. The Journal of Headache and Pain. 2025;26(1):191. doi:10.1186/s10194-025-02114-z.
The Putative Role of Neuroinflammation in the Complex Pathophysiology of Migraine: From Bench to Bedside. Biscetti L, Cresta E, Cupini LM, Calabresi P, Sarchielli P. Neurobiology of Disease. 2023;180:106072. doi:10.1016/j.nbd.2023.106072.
Migraine. Ashina M. The New England Journal of Medicine. 2020;383(19):1866-1876. doi:10.1056/NEJMra1915327.
Effects of Selected Dietary Supplements on Migraine Prophylaxis: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Talandashti MK, Shahinfar H, Delgarm P, Jazayeri S. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2025;46(2):651-670. doi:10.1007/s10072-024-07794-0.
Non-Opioid Analgesics for the Prevention of Chronic Postsurgical Pain: A Systematic Review and Network Meta-Analysis. Doleman B, Mathiesen O, Sutton AJ, et al. British Journal of Anaesthesia. 2023;130(6):719-728. doi:10.1016/j.bja.2023.02.041.
Pharmacotherapy for the Prevention of Chronic Pain After Surgery in Adults: An Updated Systematic Review and Meta-Analysis. Carley ME, Chaparro LE, Choinière M, et al. Anesthesiology. 2021;135(2):304-325. doi:10.1097/ALN.0000000000003837.
Nutritional Intervention in Chronic Pain: An Innovative Way of Targeting Central Nervous System Sensitization?. Nijs J, Tumkaya Yilmaz S, Elma Ö, et al. Expert Opinion on Therapeutic Targets. 2020;24(8):793-803. doi:10.1080/14728222.2020.1784142.
Persistent Postsurgical Pain: Risk Factors and Prevention. Kehlet H, Jensen TS, Woolf CJ. Lancet (London, England). 2006;367(9522):1618-25. doi:10.1016/S0140-6736(06)68700-X.
Clinical Efficacy of Magnesium in Perioperative Pain Management: A Narrative Review. Ahmadzadeh S, Wentling JG, Ford BM, et al. Current Pain and Headache Reports. 2025;29(1):117. doi:10.1007/s11916-025-01422-y.
Perioperative Systemic Magnesium to Minimize Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials. De Oliveira GS, Castro-Alves LJ, Khan JH, McCarthy RJ. Anesthesiology. 2013;119(1):178-90. doi:10.1097/ALN.0b013e318297630d.
Effects of Magnesium Sulfate Administration in Attenuating Chronic Postsurgical Pain in Rats. Kido K, Katagiri N, Kawana H, et al. Biochemical and Biophysical Research Communications. 2021;534:395-400. doi:10.1016/j.bbrc.2020.11.069.
Effect of Hypovitaminosis D on Postoperative Pain Outcomes and Short-Term Health-Related Quality of Life After Knee Arthroplasty: A Cohort Study. Lee A, Chan SKC, Samy W, Chiu CH, Gin T. Medicine. 2015;94(42):e1812. doi:10.1097/MD.0000000000001812.
Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: A Cohort Study. Kim Y, Zhang F, Su K, et al. Journal of General Internal Medicine. 2020;35(9):2545-2552. doi:10.1007/s11606-020-06001-y.
Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis. Gatti A, Lazzari M, Gianfelice V, et al. Pain Medicine (Malden, Mass.). 2012;13(9):1121-30. doi:10.1111/j.1526-4637.2012.01432.x.
Efficacy and Safety of Magnesium for the Management of Chronic Pain in Adults: A Systematic Review. Park R, Ho AM, Pickering G, et al. Anesthesia and Analgesia. 2020;131(3):764-775. doi:10.1213/ANE.0000000000004673.
Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. Chou R, Fanciullo GJ, Fine PG, et al. The Journal of Pain. 2009;10(2):113-30. doi:10.1016/j.jpain.2008.10.008.
A Systematic Review and Meta-Analysis on the Role of Nutraceuticals in the Management of Neuropathic Pain in in Vivo Studies. Ilari S, Proietti S, Russo P, et al. Antioxidants (Basel, Switzerland). 2022;11(12):2361. doi:10.3390/antiox11122361.
Exploring Mechanistic Insights by Carotenoids in Neuropathic and Inflammatory Pain. Abbaszadeh F, Jorjani M, Amirian R, Fakhri S, Khan H. Current Neuropharmacology. 2025;:CN-EPUB-149147. doi:10.2174/011570159X371386250619064416.
The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
Migraine Headache Prophylaxis. Moreland P, Gaffney B, Lanham JS. American Family Physician. 2025;111(5):443-450.
Evidence-Based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Holland S, Silberstein SD, Freitag F, et al. Neurology. 2012;78(17):1346-53. doi:10.1212/WNL.0b013e3182535d0c.
Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur. Tepper SJ, Tepper K. Current Pain and Headache Reports. 2025;29(1):33. doi:10.1007/s11916-025-01358-3.
Management of Headache (2023). Jane Abanes PhD DNP MSN/Ed PMHCNS PMHNP-BC RN, Natasha M. Antonovich PharmD BCPS, Andrew C. Buelt DO, et al. Department of Veterans Affairs.
Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review. von Luckner A, Riederer F. Headache. 2018;58(2):199-209. doi:10.1111/head.13217.
Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-Analysis of Randomized Controlled Trials. Chiu HY, Yeh TH, Huang YC, Chen PY. Pain Physician. 2016;19(1):E97-112.
Magnesium and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational and Intervention Studies. Veronese N, Demurtas J, Pesolillo G, et al. European Journal of Nutrition. 2020;59(1):263-272. doi:10.1007/s00394-019-01905-w.
Review on Headache Related to Dietary Supplements. Ariyanfar S, Razeghi Jahromi S, Togha M, Ghorbani Z. Current Pain and Headache Reports. 2022;26(3):193-218. doi:10.1007/s11916-022-01019-9.
Metabolic Treatments of Migraine. Lisicki M, Schoenen J. Expert Review of Neurotherapeutics. 2020;20(3):295-302. doi:10.1080/14737175.2020.1729130.
Efficacy of Coenzyme Q10 in Migraine Prophylaxis: A Randomized Controlled Trial. Sándor PS, Di Clemente L, Coppola G, et al. Neurology. 2005;64(4):713-5. doi:10.1212/01.WNL.0000151975.03598.ED.
The Association Between Melatonin and Episodic Migraine: A Pilot Network Meta-Analysis of Randomized Controlled Trials to Compare the Prophylactic Effects With Exogenous Melatonin Supplementation and Pharmacotherapy. Tseng PT, Yang CP, Su KP, et al. Journal of Pineal Research. 2020;69(2):e12663. doi:10.1111/jpi.12663.
Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Abouelmagd ME, Aldemerdash MA, Khatatbeh AA, et al. Current Pain and Headache Reports. 2026;30(1):25. doi:10.1007/s11916-025-01461-5.
Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Headache. 2020;60(7):1273-1299. doi:10.1111/head.13828.
Randomised Clinical Trial Comparing Melatonin 3 mg, Amitriptyline 25 mg and Placebo for Migraine Prevention. Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Journal of Neurology, Neurosurgery, and Psychiatry. 2016;87(10):1127-32. doi:10.1136/jnnp-2016-313458.
Therapeutic Role of Melatonin in Migraine Prophylaxis: A Systematic Review. Long R, Zhu Y, Zhou S. Medicine. 2019;98(3):e14099. doi:10.1097/MD.0000000000014099.
Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use During Migraines in Otherwise Healthy Participants-a Double-Blind Randomised Controlled Study. Briskey D, Skinner R, Smith C, Rao A. Pharmaceuticals (Basel, Switzerland). 2024;17(2):145. doi:10.3390/ph17020145.
Palmitoylethanolamide-Based Nutraceutical Calmux® in Preventive Treatment of Migraine. Hernández AG. Clinical Neurology and Neurosurgery. 2022;218:107282. doi:10.1016/j.clineuro.2022.107282.
Effects of Add-on Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study. Chirchiglia D, Cione E, Caroleo MC, et al. Frontiers in Neurology. 2018;9:674. doi:10.3389/fneur.2018.00674.
The Endocannabinoid System and Related Lipids as Potential Targets for the Treatment of Migraine-Related Pain. Greco R, Demartini C, Zanaboni AM, et al. Headache. 2022;62(3):227-240. doi:10.1111/head.14267.
Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering From Migraine: A Pilot Study. Papetti L, Sforza G, Tullo G, et al. Pain Research & Management. 2020;2020:3938640. doi:10.1155/2020/3938640.
Spinal Nociceptive Sensitization and Plasma Palmitoylethanolamide Levels During Experimentally Induced Migraine Attacks. De Icco R, Greco R, Demartini C, et al. Pain. 2021;162(9):2376-2385. doi:10.1097/j.pain.0000000000002223.
The Impact of Curcumin on Migraine: A Comprehensive Review. Heidari H, Shojaei M, Askari G, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023;164:114910. doi:10.1016/j.biopha.2023.114910.
Herbal Treatments for Migraine: A Systematic Review of Randomised-Controlled Studies. Lopresti AL, Smith SJ, Drummond PD. Phytotherapy Research : PTR. 2020;34(10):2493-2517. doi:10.1002/ptr.6701.
The Clinical Use of Curcumin on Neurological Disorders: An Updated Systematic Review of Clinical Trials. Mohseni M, Sahebkar A, Askari G, et al. Phytotherapy Research : PTR. 2021;35(12):6862-6882. doi:10.1002/ptr.7273.
The Synergistic Effects of Nano-Curcumin and Coenzyme Q10 Supplementation in Migraine Prophylaxis: A Randomized, Placebo-Controlled, Double-Blind Trial. Parohan M, Sarraf P, Javanbakht MH, et al. Nutritional Neuroscience. 2021;24(4):317-326. doi:10.1080/1028415X.2019.1627770.
The Effects of Nano-Curcumin Supplementation on Adipokines Levels in Obese and Overweight Patients With Migraine: A Double Blind Clinical Trial Study. Sedighiyan M, Abdolahi M, Jafari E, et al. BMC Research Notes. 2022;15(1):189. doi:10.1186/s13104-022-06074-4.
The Synergistic Effects of Ω-3 Fatty Acids and Nano-Curcumin Supplementation on Tumor Necrosis Factor (TNF)-α Gene Expression and Serum Level in Migraine Patients. Abdolahi M, Tafakhori A, Togha M, et al. Immunogenetics. 2017;69(6):371-378. doi:10.1007/s00251-017-0992-8.
Dietary Alteration of N-3 and N-6 Fatty Acids for Headache Reduction in Adults With Migraine: Randomized Controlled Trial. Ramsden CE, Zamora D, Faurot KR, et al. BMJ (Clinical Research Ed.). 2021;374:n1448. doi:10.1136/bmj.n1448.
A 12-Week Randomized Double-Blind Clinical Trial of Eicosapentaenoic Acid Intervention in Episodic Migraine. Wang HF, Liu WC, Zailani H, et al. Brain, Behavior, and Immunity. 2024;118:459-467. doi:10.1016/j.bbi.2024.03.019.
Effects of Omega-3 Fatty Acids on the Frequency, Severity, and Duration of Migraine Attacks: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Maghsoumi-Norouzabad L, Mansoori A, Abed R, Shishehbor F. Nutritional Neuroscience. 2018;21(9):614-623. doi:10.1080/1028415X.2017.1344371.
Neuroimmunological Effects of Omega-3 Fatty Acids on Migraine: A Review. Chen TB, Yang CC, Tsai IJ, et al. Frontiers in Neurology. 2024;15:1366372. doi:10.3389/fneur.2024.1366372.
Melatonin Compared to Other Treatments for Episodic Migraine: A Systematic Review and Network Meta-Analysis. Araujo Gouhie F, Alves Silva D, Rizzo Parreira B, et al. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2025;:1-7. doi:10.1017/cjn.2025.10423.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.